Key Trends Reshaping the Immunogenomics Market: Advanced Single-Cell Transcriptome Solutions Enable High-Resolution Immune Analysis Industry Transformation

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Immunogenomics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the immunogenomics market has seen swift expansion. The market size is forecasted to surge from $5.24 billion in 2024 to $6.09 billion in 2025, with a compound annual growth rate (CAGR) of 16.3%. The significant growth during the previous years can be traced back to a rise in autoimmune diseases, soaring demand for personalized medicine, heightened consciousness about immunogenomic testing, government contributions towards healthcare research, and the proliferation of the biotechnology and pharmaceutical industries.

How Will the Immunogenomics Market Size Evolve and Grow by 2029?
The projected size of the immunogenomics market is set to experience a swift expansion in the coming years. By 2029, it is predicted to reach $11.00 billion, with a compound annual growth rate (CAGR) of 15.9%. This anticipated growth through the forecast period is attributable to factors such as the rising uptake of immunogenomic-based treatments, advancements in precision medicine, increased investment in research and development, improvement of healthcare facilities, and mounting demand for diagnostic procedures. Key trends set to influence the market during this forecast period encompass technological progress in sequencing and genotyping, breakthroughs in immunogenomic testing, advances in bioinformatics and data interpretation, investments in research and development for targeted therapies, and the incorporation of artificial intelligence within the realm of immunogenomics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/immunogenomics-global-market-report

What Drivers Are Propelling the Growth of Immunogenomics Market Forward?
The growth of the immunogenomics market is forecasted to be accelerated by the growing incidence of infectious diseases. These diseases, caused by harmful microbes such as bacteria, viruses, fungi, or parasites, can be contracted directly or indirectly from another individual. The rise in infectious diseases is due to the expanding travel activities, which allows for quick transmission of pathogens across borders. Immunogenomics aids in managing infectious diseases by providing accurate analysis of host immune responses and genetic vulnerability. This minimizes guesswork in treatment by pinpointing patient-specific immune elements, enhancing diagnostics, vaccine development, and personalized therapy strategies. As an example, the UK Health Security Agency, a government entity based in the UK, reported that the number of tuberculosis cases (a contagious bacterial infection mainly impacting the lungs) in England went up to 4,850 in 2023, a 10.7% increase from the 4,380 cases reported in 2022. As a result, the escalation in the occurrences of infectious diseases is propelling the growth of the immunogenomics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28247&type=smp

Which Emerging Trends Are Transforming the Immunogenomics Market in 2025?
A key strategy of leading businesses in the immunogenomics market is to focus on the development of state-of-the-art solutions like single-cell transcriptome solutions. These innovative solutions aid in the thorough analysis of immune cell differences and facilitate a deeper comprehension of intricate immune reactions. The term 'single-cell transcriptome solution' denotes a procedure or technology which investigates the entire RNA transcripts in singular cells. This permits for an in-depth exploration of gene expression patterns and cellular variance within intricate tissues. For instance, in October 2022, a collaboration took place between Pacific Biosciences of California Inc., located in the USA, Broad Institute of MIT and Harvard, located in the UK, and 10x Genomics Inc., also based in the USA. The collaboration resulted in the launch of a Multiplexed Arrays Sequencing (MAS-Seq) kit that allows cost-effective, high-throughput sequencing of complete transcripts. With this kit, users can successfully carry out a cost-effective single-cell transcriptome solution that can detect novel RNA isoforms and mutations accurately. The kit enhances sequencing throughput by combining cDNA molecules, increasing it 16 times. It's compatible with with 10x Genomics' single-cell technology and PacBio's sequencers. The solution is advantageous in research as it enables exploring cellular heterogeneity at the isoform level, pushing forward disease research and biomarker discovery.

What Are the Key Segments in the Immunogenomics Market?
The immunogenomics market covered in this report is segmented as

1) By Product Type: Instruments, Consumables, Software, Services
2) By Technology: Next-Generation Sequencing, Microarray, Polymerase Chain Reaction, Other Technologies
3) By Application: Oncology, Infectious Diseases, Autoimmune Disorders, Transplantation, Other Applications
4) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:
1) By Instruments: Sequencers, Microarray scanners, Flow cytometers
2) By Consumables: Reagents, Kits, Assay panels
3) By Software: Data analysis software, Bioinformatics tools, Visualization platforms
4) By Services: Sequencing services, Genomic profiling, Bioinformatics support

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28247&type=smp

Who Are the Key Players Shaping the Immunogenomics Market's Competitive Landscape?
Major companies operating in the immunogenomics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., BGI Group, GenScript Biotech Corporation, CareDx Inc., Oxford Nanopore Technologies plc, Genewiz LLC, Adaptive Biotechnologies Corporation, GenomOncology LLC, Personalis Inc., Variantyx Inc., CD Genomics Inc., Sengenics Corporation, GeneCentric Therapeutics Inc., Immunogenomics Inc., ImmuQuad Biotechnologies Inc., Neomics Pharmaceuticals LLC, Yemaachi Biotech Ltd., and BioAnalytica Biotechnology Systems Inc.

What Geographic Markets Are Powering Growth in the Immunogenomics Market?
North America was the largest region in the immunogenomics market in 2024. The regions covered in immunogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28247

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.